-
公开(公告)号：EP1962584A2
公开(公告)日：2008-09-03
申请号：EP06849173.7
申请日：2006-11-16
发明人： HORNER, Allison, Anne, Byers , COMBS, Katherin E. , DESAUVAGE, Frederic , FAN, Liangfen , FILVAROFF, Ellen , IRVING, Bryan , JUNUTULA, Jagath Reddy , MASSEY, Erin Marie , MCLAIN, Dina Rebecca , MINZE, Laurie Jeanette , MONTGOMERY, Charles, A. , PAYNE, Bobby Joe , PHILLIPS, Heidi , RANGEL, Carolina , SHI, Zheng-zheng , SPARKS, Mary Jean , STALA, Joy, Anne , TOWNSEND, Teresa Gail , VOGEL, Peter , SEVAUX, Tracy Ellen Willis
IPC分类号： A01K67/027 , A61K49/00
CPC分类号： C12Q1/6883 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C12N15/8509 , C12Q2600/158
摘要： The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
-
2.发明公开
公开(公告)号：EP1871163A2
公开(公告)日：2008-01-02
申请号：EP06770779.4
申请日：2006-05-18
发明人： COMBS, Katherin , CULBERTSON, Ling Ling , DESAUVAGE, Frederic , DING, Zhiyong , EDWARDS, Joel , GIRGIS, Rosemary , JUNGE, Harald , JUNUTULA, Jagath Reddy , MASSEY, Erin Marie , MCLAIN, Dina Rebecca , MONTGOMERY, Charles A. , PAYNE, Bobby Joe , PHILLIPS, Heidi , QIAN, Ni Nancy , RANGEL, Carolina , SHI, Zheng-Zheng , SPARKS, Mary Jean , STALA, Joy , VOGEL, Peter , SEVAUX, Tracy, Ellen, Willis , YE, Weilan , HORNER, Allison, Ann, Byers
IPC分类号： A01K67/027 , C12N15/85 , G01N33/00
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , C12N15/8509
摘要： The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
-
公开(公告)号：EP3269737A1
公开(公告)日：2018-01-17
申请号：EP17174600.1
申请日：2009-01-14
申请人： Genentech, Inc.
发明人： CHEN, Yvonne , DENNIS, Mark , DORNAN, David , ELKINS, Kristi , JUNUTULA, Jagath Reddy , POLSON, Andrew , ZHENG, Bing
IPC分类号： C07K16/28 , A61K39/395 , C12N15/13 , A61P35/00 , A61K51/10 , A61K39/00 , A61K38/05 , A61K45/06 , A61K31/537 , C07K16/30 , G01N33/574 , A61K47/68
CPC分类号： C07K16/2803 , A61K31/537 , A61K38/05 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6811 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K2039/505 , C07K16/3061 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , G01N33/57492
摘要： The present invention is directed to humanized and conjugated antibodies against CD79b useful for the treatment of hematopoietic tumor in mammals and to methods of using those antibodies for the same.
摘要翻译： 本发明涉及用于治疗哺乳动物造血肿瘤的人源化抗CD79b抗体和结合抗体以及使用这些抗体的方法。
-
公开(公告)号：EP2640727A1
公开(公告)日：2013-09-25
申请号：EP11793586.6
申请日：2011-11-16
申请人： Genentech, Inc.
IPC分类号： C07D491/12 , A61K31/535 , A61K39/00
CPC分类号： C07D491/12
摘要： Linker-drug intermediates of Formula I are conjugated to antibodies to form antibody-drug conjugates where the drug moiety is an N-methylalaninyl-maytansinoid. L is Formula IA; E is Formula IB or Formula IC; n is 2, 3, 4, 5, or 6; m is 2, 3 or 4; and q is 0 or 1.
摘要翻译： 式I的连接体 - 药物中间体与抗体偶联以形成抗体 - 药物偶联物，其中药物部分是N-甲基丙氨酰基 - 美登木素生物碱。 L是式IA; E是公式IB或公式IC; n是2,3,4,5或6; m是2,3或4; q是0或1。
-
公开(公告)号：EP3088004B1
公开(公告)日：2018-03-28
申请号：EP16158429.7
申请日：2005-09-22
申请人： Genentech, Inc.
发明人： EIGENBROT, Charles W. , JUNUTULA, Jagath Reddy , LOWMAN, Henry , RAAB, Helga E. , VANDLEN, Richard
IPC分类号： A61K47/50
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D) p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
-
公开(公告)号：EP1791565B1
公开(公告)日：2016-04-20
申请号：EP05811919.9
申请日：2005-09-22
申请人： Genentech, Inc.
发明人： EIGENBROT, Charles W. , JUNUTULA, Jagath Reddy , LOWMAN, Henry , RAAB, Helga E. , VANDLEN, Richard
IPC分类号： A61K47/48
CPC分类号： A61K47/6803 , A01K2267/0331 , A61K45/06 , A61K47/6817 , A61K47/6851 , A61K47/6889 , C07K16/00 , C07K16/32 , C07K2317/21 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/624
摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D) p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
-
公开(公告)号：EP2640727B1
公开(公告)日：2015-05-13
申请号：EP11793586.6
申请日：2011-11-16
申请人： Genentech, Inc.
IPC分类号： C07D491/12 , A61K31/535 , A61K39/00
CPC分类号： C07D491/12
-
8.发明公开
公开(公告)号：EP2176295A1
公开(公告)日：2010-04-21
申请号：EP08772549.5
申请日：2008-07-15
申请人： Genentech, Inc.
发明人： CHEN, Yvonne , DENNIS, Mark , ELKINS, Kristi , JUNUTULA, Jagath Reddy , POLSON, Andrew , ZHENG, Bing
IPC分类号： C07K16/28 , A61K39/395 , C12N15/13 , A61K47/48 , A61P35/02
CPC分类号： C07K16/2803 , A61K39/39541 , A61K39/39558 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , Y02A50/412
摘要： The present invention is directed to humanized and conjugated antibodies against CD79b useful for the treatment of hematopoietic tumor in mammals and to methods of using those antibodies for the same.
-
公开(公告)号：EP4427805A2
公开(公告)日：2024-09-11
申请号：EP24175757.4
申请日：2009-01-14
申请人： Genentech, Inc.
发明人： CHEN, Yvonne , DENNIS, Mark , DORNAN, David , ELKINS, Kristi , JUNUTULA, Jagath Reddy , POLSON, Andrew , ZHENG, Bing
IPC分类号： A61P7/06
CPC分类号： A61K51/1027 , A61K2039/50520130101 , C07K2317/9220130101 , C07K2317/3420130101 , A61K47/6811 , A61K47/6849 , A61K47/6867 , C07K16/2803 , A61K38/05 , A61K31/537 , A61P11/00 , A61P13/12 , A61P15/08 , A61P17/00 , A61P19/02 , A61P21/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P33/00 , A61P35/00 , A61P35/02 , A61P37/06 , A61P43/00 , A61P5/14 , A61P7/00 , A61P9/00 , Y02A50/30 , A61K47/68031 , A61K47/68033
摘要： The present invention is directed to humanized and conjugated antibodies against CD79b useful for the treatment of hematopoietic tumor in mammals and to methods of using those antibodies for the same.
-
10.发明公开IMMUNOCONJUGATES COMPRISING ANTI-HER2 ANTIBODIES AND PYRROLOBENZODIAZEPINES 审中-公开包含抗HER2抗体和吡咯并苯并二氮杂的免疫偶联物
公开(公告)号：EP3197500A1
公开(公告)日：2017-08-02
申请号：EP15779065.0
申请日：2015-09-16
申请人： Genentech, Inc.
发明人： CHEN, Xiaocheng , DENNIS, Mark , JUNUTULA, Jagath Reddy , PHILLIPS, Gail Lewis , PILLOW, Thomas Harden , SLIWKOWSKI, Mark X.
CPC分类号： A61K31/5517 , A61K39/39558 , A61K47/48384 , A61K47/48584 , A61K47/6803 , A61K47/6855 , A61K47/6869 , C07K16/005 , C07K16/32 , C07K2317/24 , C07K2317/92
摘要： The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
摘要翻译： 本发明提供了包含抗HER2抗体的免疫缀合物及其使用方法。 提供免疫缀合物，其包含抗体和细胞毒性剂，其中细胞毒剂是中心连接的吡咯并苯并二氮杂。 免疫缀合物具有式Ab-（L-D）p，其中：a）Ab是权利要求1至16中任一项的抗体; b）L是连接子; c）D是中心连接的吡咯并苯并二氮杂; 和d）p范围从1-8。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.04 秒)
